Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Melperone is an atypical antipsychotic of the butyrophenone chemical class and is structurally related to haloperidol. It has been used for over 30 years in the European Union for the treatment of sleep disorders, confusion states (especially in geriatric patients), psychomotor dysfunction associated with psychiatric and alcohol-dependent patients, severe agitation, schizophrenia-related psychosis (including treatment-resistant cases), anxiety disorders (with anxiolytic properties), and certain behavioral disorders. It is also considered for psychosis related to Parkinson’s disease. Melperone acts primarily as a dopamine D2 receptor antagonist with low affinity and rapid dissociation from D2 receptors; it also exerts effects on serotonin receptors (5-HT2A) contributing to its anxiolytic and mood-stabilizing effects. The drug is known for its relatively mild side effect profile compared to typical antipsychotics[1][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on melperone.